Fosnetupitant / palonosetron Side Effects

Medically reviewed by Drugs.com. Last updated on Aug 12, 2023.

Applies to fosnetupitant / palonosetron: intravenous powder for solution, intravenous solution.

Serious side effects

Along with its needed effects, fosnetupitant/palonosetron may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking fosnetupitant / palonosetron:

Incidence not known

• Agitation
• confusion
• cough or hoarseness
• dizziness
• fast heartbeat
• fever
• hearing or seeing things that are not there
• hives, itching, skin rash
• irritation
• joint pain, stiffness or swelling
• muscle twitching
• overactive reflexes
• poor coordination
• redness of the skin
• shivering
• sweating
• swelling of the eyelids, face, lips, hands, or feet
• tightness in the chest
• trembling or shaking
• trouble breathing or swallowing

Other side effects

Some side effects of fosnetupitant / palonosetron may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Headache
• unusual tiredness or weakness

Less common

• Constipation
• heartburn
• indigestion
• stomach discomfort, upset, or pain

For Healthcare Professionals

Applies to fosnetupitant / palonosetron: intravenous powder for injection, intravenous solution.

Gastrointestinal

Frequency not reported: Constipation, dyspepsia

Palonosetron:

Common (1% to 10%): Constipation, dyspepsia^[Ref]

Other

Frequency not reported: Asthenia, fatigue

Palonosetron:

Common (1% to 10%): Asthenia, fatigue^[Ref]

Nervous system

Frequency not reported: Headache, serotonin syndrome

Palonosetron:

Common (1% to 10%): Headache^[Ref]

Dermatologic

Frequency not reported: Erythema

Palonosetron:

Common (1% to 10%): Erythema^[Ref]

Hepatic

Palonosetron:

Uncommon (0.1% to 1%): Elevated AST, elevated ALT, elevated total bilirubin^[Ref]

Approximately 0.6% of patients given 0.5 mg of palonosetron developed AST greater than 3 times the upper limit of normal (ULN) and/or ALT greater than 3 x ULN with total bilirubin greater than ULN. Approximately 0.2% of patients given the same dose of palonosetron developed AST greater than 10 x ULN and/or ALT greater than 10 x ULN with total bilirubin greater than ULN, and approximately 0.1% of patients developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN.

Approximately 0.3% of patients given oral formulations of netupitant-palonosetron developed AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than ULN, and AST greater than 3 x ULN and/or ALT greater than 3 x ULN with total bilirubin greater than or equal to 2 x ULN occurred in up to 0.1% of patients.^[Ref]

Hypersensitivity

Frequency not reported: Hypersensitivity reactions^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer